Alpha-Mannosidosis

Alpha-Mannosidosis

Overview

Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder caused by deficient activity of the enzyme alpha-mannosidase (MAN2B1), leading to accumulation of mannose-rich oligosaccharides in lysosomes throughout the body[@unveiling]. This progressive multisystem disease primarily affects the central nervous system, skeletal system, and immune system. Clinical manifestations include intellectual disability, hearing loss, skeletal abnormalities, and immune dysfunction. The disease is estimated to affect approximately 1 in 500,000 to 1 in 1,000,000 births worldwide.

Genetics

Gene Defect

Alpha-mannosidosis is caused by homozygous or compound heterozygous pathogenic variants in the MAN2B1 gene (chromosome 19p13.2), which encodes the enzyme lysosomal alpha-mannosidase[@unveiling]. This enzyme is required for the stepwise degradation of N-linked glycoproteins, cleaving alpha-1,2, alpha-1,3, and alpha-1,6 mannose residues from oligosaccharide chains.

Inheritance Pattern

The disease follows autosomal recessive inheritance:

• Both parents must carry one pathogenic MAN2B1 variant
• Each pregnancy has a 25% chance of an affected child
• Heterozygous carriers are typically asymptomatic

Common Variants

Over 80 pathogenic variants have been identified:

• p.R750W — Common in European populations
• p.D620G — Frequent in some populations
• p.E953K — Associated with milder phenotype
• Various missense, nonsense, splice site, and deletion variants

Pathophysiology

Enzyme Deficiency

...

Alpha-Mannosidosis

Overview

Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder caused by deficient activity of the enzyme alpha-mannosidase (MAN2B1), leading to accumulation of mannose-rich oligosaccharides in lysosomes throughout the body[@unveiling]. This progressive multisystem disease primarily affects the central nervous system, skeletal system, and immune system. Clinical manifestations include intellectual disability, hearing loss, skeletal abnormalities, and immune dysfunction. The disease is estimated to affect approximately 1 in 500,000 to 1 in 1,000,000 births worldwide.

Genetics

Gene Defect

Alpha-mannosidosis is caused by homozygous or compound heterozygous pathogenic variants in the MAN2B1 gene (chromosome 19p13.2), which encodes the enzyme lysosomal alpha-mannosidase[@unveiling]. This enzyme is required for the stepwise degradation of N-linked glycoproteins, cleaving alpha-1,2, alpha-1,3, and alpha-1,6 mannose residues from oligosaccharide chains.

Inheritance Pattern

The disease follows autosomal recessive inheritance:

• Both parents must carry one pathogenic MAN2B1 variant
• Each pregnancy has a 25% chance of an affected child
• Heterozygous carriers are typically asymptomatic

Common Variants

Over 80 pathogenic variants have been identified:

• p.R750W — Common in European populations
• p.D620G — Frequent in some populations
• p.E953K — Associated with milder phenotype
• Various missense, nonsense, splice site, and deletion variants

Pathophysiology

Enzyme Deficiency

Lysosomal alpha-mannosidase (LAMAN, EC 3.2.1.24) normally degrades mannose-rich oligosaccharides generated from glycoprotein catabolism[@unveiling]. When deficient:

• Oligosaccharides accumulate within lysosomes
• Cytoplasmic vacuolization occurs in multiple cell types
• Cellular function becomes progressively impaired

Accumulated Substrates

The primary accumulated substrates are:

• Man₂GlcNAc₂ (Man₂) — Major stored oligosaccharide
• Man₃GlcNAc₂ (Man₃) — Also significantly accumulated
• Various high-mannose type N-glycans

Tissue Pathology

• [Neurons](/entities/neurons) — Cytoplasmic vacuolization, eventual neuronal loss
• Oligodendrocytes — Myelin breakdown, white matter abnormalities
• Skeletal muscle — Fiber atrophy, vacuolar changes
• Bone — Dysostosis multiplex pattern
• Immune cells — Reduced lymphocyte function

Clinical Features

Severity Spectrum

Alpha-mannosidosis presents with a spectrum of severity:

• Severe (Type I) — Early onset, rapid progression, profound intellectual disability
• Moderate (Type II) — Typical presentation in childhood
• Mild (Type III) — Later onset, slower progression

Central Nervous System

• Intellectual disability — Present in nearly all patients
• IQ typically ranges from 40-70
• Delayed speech and language development
• Learning difficulties requiring special education
• Motor delays — Delayed walking, coordination problems
• Ataxia — Cerebellar involvement causing gait instability
• Seizures — Occur in approximately 15-20% of patients
• Behavioral problems — Autism-like features, hyperactivity

Auditory System

• Sensorineural hearing loss — Progressive, typically moderate to severe
• Otitis media — Recurrent middle ear infections common
• Speech development — Affected by hearing loss

Skeletal System

• Dysostosis multiplex — Characteristic skeletal pattern:
• Vertebral abnormalities (platyspondyly, odontoid dysplasia)
• thickened calvaria
• J-shaped sella
• Broad ribs
• Expanded medullary cavities in long bones
• Coxa valga
• Metaphyseal widening
• Growth retardation — Short stature common
• Joint laxity — Increased flexibility
• Recurrent infections — Sinopulmonary infections

Immune System

• Immunodeficiency — Variable humoral and cellular defects
• Recurrent infections — Particularly respiratory
• Autoimmune phenomena — Some patients develop autoimmune disorders

Other Features

• Facial dysmorphism — Coarse facial features, macroglossia
• Dental abnormalities — Delayed eruption, enamel defects
• Hepatosplenomegaly — Mild to moderate liver/spleen enlargement
• Cardiac involvement — Rare, but valvular abnormalities reported

Diagnosis

Clinical Suspicion

Diagnosis should be suspected in individuals with:

• Developmental delay/intellectual disability
• Hearing loss
• Characteristic skeletal abnormalities
• Recurrent infections
• Family history of the disorder

Biochemical Testing

• Enzyme assay — Reduced alpha-mannosidase activity in leukocytes or fibroblasts
• Urinary oligosaccharides — Elevated mannose-rich oligosaccharides
• Plasma/serum — Elevated chitotriosidase may be present

Genetic Testing

• MAN2B1 sequencing — Identifies pathogenic variants
• Deletion/duplication analysis — Detects larger rearrangements
• Carrier testing — Available for at-risk family members
• Prenatal diagnosis — Possible for at-risk pregnancies

Imaging

• Skeletal survey — Shows dysostosis multiplex pattern
• Brain MRI — May show white matter changes, cerebellar atrophy
• Audiometry — Documents hearing loss
• Ophthalmologic exam — May show lens opacities

Treatment

Enzyme Replacement Therapy

Velmanase alfa (Lamzede) is the first and only approved enzyme replacement therapy for alpha-mannosidosis[@exemplifying]:

• Recombinant human alpha-mannosidase
• Weekly intravenous infusion
• Reduces mannose-rich oligosaccharide accumulation
• Improves endurance and motor function
• Approved in Europe (2023) and under review in other regions

Hematopoietic Stem Cell Transplantation

HSCT has been attempted with mixed results[@unveiling]:

• Can provide source of normal enzyme
• Carries significant risks
• May stabilize neurological progression if done early
• Not currently standard of care

Supportive Management

• Early intervention services — Physical, occupational, speech therapy
• Hearing aids — For sensorineural hearing loss
• Educational support — Individualized education plans
• Infection prevention — Prompt treatment of infections
• Orthopedic management — For skeletal complications
• Cardiac monitoring — Regular echocardiography

Experimental Approaches

• Gene therapy — AAV-mediated MAN2B1 delivery in development
• Substrate reduction therapy — Under investigation
• Chaperone therapy — Pharmacological chaperones in development
• mRNA therapy — mRNA-based protein delivery being explored

Prognosis

Life Expectancy

• Severe forms — Often fatal in childhood or early adulthood
• Moderate forms — Survival into adulthood common
• Mild forms — Normal or near-normal life expectancy

Disease Progression

• Progressive deterioration common
• Loss of motor skills over time
• Increasing reliance on support
• Respiratory complications major cause of morbidity

Quality of Life

• Significant disability in most patients
• Intellectual disability limits independence
• Physical limitations compound functional deficits
• Caregiver burden substantial

Research Directions

Biomarker Development

• Urinary oligosaccharides — Disease burden marker
• Plasma MAN2B1 activity — Therapeutic response
• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain — Neurodegeneration marker

New Therapies

• Next-generation enzyme formulations
• Gene therapy vectors with better CNS penetration
• Combination approaches
• Symptom-targeted interventions

Natural History Studies

• Understanding disease progression
• Identifying predictors of outcome
• Optimizing timing of interventions

See Also

• [MAN2B1 Gene](/genes/man2b1) — Causative gene
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders) — Disease category
• [Pompe Disease](/diseases/pompe-disease) — Another glycogen storage disorder
• [Fabry Disease](/diseases/fabry-disease) — Another lysosomal storage disorder

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Unveiling alpha-mannosidosis in Iraqi children: A series of clinically and genetically characterized cases with novel MAN2B1 variant.](https://pubmed.ncbi.nlm.nih.gov/41567994/) (2026 Mar) - Molecular genetics and metabolism reports
• [Exemplifying a measurement validation strategy for rare- and ultra-rare diseases: measuring what matters in alpha-mannosidosis.](https://pubmed.ncbi.nlm.nih.gov/41673877/) (2026 Feb 11) - Orphanet journal of rare diseases
• [Automated bone age assessment in rare pediatric growth disorders: a comparative study using Deeplasia.](https://pubmed.ncbi.nlm.nih.gov/41727682/) (2026) - Frontiers in endocrinology
• [Alpha-mannosidosis](https://pubmed.ncbi.nlm.nih.gov/41699219/) (2026 Feb) - MMW Fortschritte der Medizin
• [Alpha-mannosidosis due to a novel MAN2B1 truncating mutation in a Chinese patient: a new report and long-term follow-up.](https://pubmed.ncbi.nlm.nih.gov/41530594/) (2026 Jan 13) - Documenta ophthalmologica. Advances in ophthalmology

References